1-5 of 5
Paolo G Vigneri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

“Real-life” Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia

Roberto Latagliata, MD, Fabio Stagno, MD PhD, Mario Annunziata, MD, Elisabetta Abruzzese, Alessandra Iurlo, MD, Nicola Sgherza, Carmen Fava, Antonella Gozzini, MD, Gianfranco Giglio, Federica Sorà, Sabrina Leonetti Crescenzi, MD, Monica Bocchia, MD, Monica Crugnola, MD, Gabriele Gugliotta, MD, Isabella Capodanno, MD, Sara Galimberti, MD PhD, Costanzo Feo, MD, Raffaele Porrini, Patrizia Pregno, MD, Massimo Breccia, MD, Paolo G Vigneri, MDPhD, Malgorzata Monika Trawinska, Attilio Guarini, Giuliana Alimena, MD
Journal: Blood
Blood (2014) 124 (21): 5530.
https://doi.org/10.1182/blood.V124.21.5530.5530
Published: 2014
Journal Articles

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis

Cesarina Giallongo, Nunziatina Parrinello, Daniele Tibullo, Piera La Cava, Alessandra Romano, Annalisa Chiarenza, MD, PhD, Fabio Stagno, MD, Paolo G. Vigneri, MD/PhD, Giuseppe A. Palumbo, Francesco Di Raimondo, MD
Journal: Blood
Blood (2013) 122 (21): 2711.
https://doi.org/10.1182/blood.V122.21.2711.2711
Published: 2013
Journal Articles

High BCR-ABL/GUS IS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Paolo G Vigneri, MD/PhD, Fabio Stagno, MD, Stefania Stella, PhD, Alessandra Cupri, Stefano Forte, Michele Massimino, PhD, Agostino Antolino, MD, Clementina Caracciolo, Laura Nocilli, Stefana Impera, Caterina Musolino, MD, Diamante Turri, Mario Russo, MD, Carmen Tomaselli, Michele Rizzo, MD, Maurizio Musso, Fortunato Morabito, MD, Luciano Levato, Livia Manzella, MD/PhD, Martin C Muller, MD, Andreas Hochhaus, MD, Francesco Di Raimondo, MD
Journal: Blood
Blood (2013) 122 (21): 1495.
https://doi.org/10.1182/blood.V122.21.1495.1495
Published: 2013
Journal Articles

The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate

Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Alessandra Iurlo, MD, Elisabetta Abruzzese, MD, PhD, Francesco Albano, Paolo G Vigneri, MD/PhD, Francesco Cavazzini, Ester Orlandi, MD, Patrizia Pregno, MD, Mario Annunziata, MD, Piero Galieni, MD, Enrico Montefusco, Carmen Fava, MD, Francesca Palandri, Claudia Venturi, Simona Soverini, Nicoletta Testoni, BS, Giuliana Alimena, Giuseppe Saglio, Fabrizio Pane, MD, Giovanni Martinelli, MD, Michele Cavo, MD, Michele Baccarani, MD, Gianantonio Rosti
Journal: Blood
Blood (2013) 122 (21): 1486.
https://doi.org/10.1182/blood.V122.21.1486.1486
Published: 2013
Journal Articles

High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.

Paolo G Vigneri, Fabio Stagno, Stefania Stella, Alessandra Cupri, Stefano Forte, Michele Massimino, Agostino Antolino, MD, Clementina Caracciolo, Laura Nocilli, Stefana Impera, Caterina Musolino, MD, Diamante Turri, Mario Russo, Carmen Tomaselli, Michele Rizzo, Maurizio Musso, Fortunato Morabito, Luciano Levato, Livia Manzella, Martin Mueller, MD, Francesco Di Raimondo, MD
Journal: Blood
Blood (2012) 120 (21): 2790.
https://doi.org/10.1182/blood.V120.21.2790.2790
Published: 2012